Corvus Pharmaceuticals (CRVS) Total Current Liabilities (2015 - 2026)

Corvus Pharmaceuticals' Total Current Liabilities history runs 12 years deep, the most recent figure standing at $12.1 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 30.51% year-over-year to $12.1 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 30.51% increase from a year earlier, with the FY2025 full-year figure at $9.4 million, down 73.5% from the prior year.
• Total Current Liabilities improved to $12.1 million in Q1 2026 per CRVS's latest filing, from $9.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $46.4 million in Q3 2024 and bottomed at $6.7 million in Q1 2024.
• The 5-year median for Total Current Liabilities is $9.3 million (2025), against an average of $13.2 million.
• Across the five-year window, Total Current Liabilities jumped 535.79% in 2024 and slumped 82.6% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $10.8 million in 2022, then sank by 36.11% to $6.9 million in 2023, then soared by 415.39% to $35.4 million in 2024, then plunged by 73.5% to $9.4 million in 2025, then climbed by 29.1% to $12.1 million in 2026.
• Per Business Quant, the three latest CRVS Total Current Liabilities figures stand at $12.1 million (Q1 2026), $9.4 million (Q4 2025), and $8.1 million (Q3 2025).